4,5-Dihydro-4-R-6-(4-pyridinyl)-3(2H)-pyridazinone (IA) or pharmaceutically-acceptable acid-addition salt thereof, where R is hydrogen or methyl, is shown as the active component in cardiotonic composition and method for increasing cardiac contractility in a patient requiring such treatment. Also shown is the preparation of IA by reacting a lower-alkyl 2-R-4-(BN)-4-cyano-4-(4-pyridinyl)butanoate with hydrazine, where R is hydrogen or methyl, and BN is 4-morpholinyl, 1-piperidinyl or 1-pyrrolidinyl.
4,5-二氢-4-R-6-(4-
吡啶基)-3(2H)-
吡啶嗪酮(IA)或其药学上可接受的酸盐加合物被展示为心力衰竭组合物中的活性成分,以及用于增加需要此类治疗的患者的心脏收缩力的方法。还展示了通过将较低烷基的2-R-4-(BN)-4-
氰基-4-(4-
吡啶基)
丁酸酯与
肼反应制备IA的方法,其中R为氢或甲基,BN为4-
吗啡啉基,1-
哌啶基或1-
吡咯烷基。